VACCINE
VOL. 19, NO. 25-26; MAY 14, 2001
REVIEWS
Rubella eradication 3311-3319
Stanley A. Plotkin
Live attenuated vaccines against influenza; an historical review 3320-3330
M.D. Wareing and G.A. Tannock
Neonatal and early life vaccinology 3331-3346
Claire-Anne Siegrist
CONFERENCE REPORT
Pneumococcal conjugate vaccines in Europe, Berlin, Germany, 23-25 3347-3354
August 2000. Report of a European Advisory Board meeting
Heinz-J. Schmitt
SHORT COMMUNICATION
Rinderpest virus (RPV) ISCOM vaccine induces protection in cattle against 3355-3359
virulent RPV challenge
Hiroshi Kamata et al.
Effect of pre-existing immunity for systemic and mucosal immune 3360-3368
responses to intranasal immunization with group B Streptococcus type III
capsular polysaccharide-chole ra toxin B subunit conjugate
Xuzhuang Shen et al.
REGULAR PAPERS
A protective cocktail vaccine against murine cutaneous leishmaniasis with 3369-3375
DNA encoding cysteine proteinases of Leishmania major
Sima Rafati, Ali-Hatef Salmanian, Tahere Taheri, Manije Vafa and Nicolas
Fasel
Antibodies against a truncated Staphylococcus aureus fibronectin-binding 3376-3383
protein protect against dissemination of infection in the rat
Anna Rennermalm et al.
Enhanced immunogenicity of a contraceptive vaccine using diverse 3384-3389
synthetic carriers with permissible adjuvant
Anushree Gupta, Rahul Pal, Sarita Ahlawat, Prakash Bhatia and Om Singh
Evaluation of cross-reactive antigens as determinants of cross-bactericidal 3390-3398
activity in pathogenic and commensal Neisseria
S. Sánchez, G. Troncoso, C.M. Ferreirós and M.T. Criado
Formulation and characterisation of Bordetella pertussis fimbriae as novel 3399-3407
carrier proteins for Hib conjugate vaccines
Annette Crowley-Luke, Karen Reddin, Andrew Gorringe, Michael J.
Hudson and Andrew Robinson
Characterization of HIV-1 Tat proteins mutated in the transactivation 3408-3419
domain for prophylactic and therapeutic application
Monica Betti et al.
Comparison of cost-effectiveness of preventive and reactive mass 3420-3431
immunization campaigns against meningococcal meningitis in West Africa:
a theoretical modeling analysis
Isabelle Parent du Châtelet, Bradford D. Gessner and Alfred da Silva
The virulence for gnotobiotic pigs of live attenuated vaccine strains of 3432-3436
Salmonella enterica serovars Typhimurium and Enteritidis
P.A. Barrow, K. Page and M.A. Lovell
A multi-center controlled study of rapid hepatitis B vaccination using a 3437-3443
novel triple antigen recombinant vaccine
Michael D. Young, M.H. Rosenthal, Brian Dickson, Wei Du and Willis C.
Maddrey
Comparison of large-scale mammalian cell culture systems with egg culture 3444-3450
for the production of influenza virus A vaccine strains
Julia A. Tree, Catherine Richardson, Anthony R. Fooks, J. Christopher
Clegg and Denis Looby
Vaccination against leprosy at Ben San Leprosy Centre, Ho Chi Minh City, 3451-3458
Vietnam
Le Van Truoc et al.
Antigenicity modulation upon peptide cyclization: application to the GH 3459-3466
loop of foot-and- mouth disease virus strain C1-Barcelona
Paula Gomes, Ernest Giralt and David Andreu
Detection and growth kinetics of SV40 preparations with different enhancer 3467-3471
element copy number
P.D. Minor, G. Dunn and P.A. Pipkin
Comparison of three different influenza vaccines in institutionalised elderly 3472-3475
V. Baldo et al.
Oral administration of hepatitis E virus- like particles induces a systemic and 3476-3484
mucosal immune response in mice
Tian-Cheng Li, Naokazu Takeda and Tatsuo Miyamura
Successful vaccination against Leishmania donovani infection in Indian 3485-3492
langur using alum-precipitated autoclaved Leishmania major with BCG
Alka Misra et al.
Influenza vaccination is safe and immunogenic when administered to 3493-3498
hospitalized patients
Bruce B. Berry, David A. Ehlert, Richard J. Battiola and Gerald Sedmak
Unusual persistence in healthy volunteers and ill patients of hyperimmune 3499-3508
immunoglobulin directed against multiple Pseudomonas O-chain and
Klebsiella serotypes after intravenous infusion
J. Bruce McClain et al.
Immunization of mice with lipopeptide antigens encapsulated in novel 3509-3517
liposomes prepared from the polar lipids of various Archaeobacteria elicits
rapid and prolonged specific protective immunity against infection with the
facultative intracellular pathogen, Listeria monocytogenes
J. Wayne Conlan, Lakshmi Krishnan, Gordon E. Willick, Girishchandra B.
Patel and G. Dennis Sprott
Comparison of different delivery systems of vaccination for the induction of 3518-3525
protection against tuberculosis in mice
Karla M. Lima et al.
Enhanced simian immunodeficiency virus-specific immune responses in 3526-3536
macaques induced by priming with recombinant Semliki Forest virus and
boosting with modified vaccinia virus Ankara
boosting with modified vaccinia virus Ankara
Charlotta Nilsson et al.
Storage at 3°C for 24 h alters the immunogenicity of pertussis vaccines 3537-3542
Christina Ann Boros, M. Hanlon, M.S. Gold and D.M. Roberton
Genetic engineering of live rabies vaccines 3543-3551
Kinjiro Morimoto et al.
Enhancing the potency of peptide-pulsed antigen presenting cells by vector- 3552-3567
driven hyperexpression of a triad of costimulatory molecule
James W. Hodge et al.
Immunogenicity of recombinant class 1 protein from Neisseria meningitidis 3568-3574
refolded into phospholipid vesicles and detergent
Olivia Niebla et al.
A mathematical model describing the thermal virus inactivation 3575-3582
Catherine Noël, Sandrine Charles, Alain Françon and Jean Pierre Flandrois
Vaccine regimen for prevention of sexually transmitted infections with 3583-3590
human papillomavirus type 16
Dariusz W. Kowalczyk, Anthony P. Wlazlo, Sara Shane and Hildegund C.J.
Ertl
Intranasal immunogenicity of a cya crp-pabA mutant of Salmonella enterica 3591-3599
serotype Typhimurium for the horse
Abhineet S. Sheoran, John F. Timoney, Steven A. Tinge, Preeti Sundaram
and Roy Curtiss III
Economic evaluation of Haemophilus influenzae type b vaccination in 3600-3605
Slovenia
Marko Pokorn, tefan Kopa, David Neubauer and Milan iman
Corrigendum 3606
Announcements I
VOL. 19, NO. 27; JUNE 14, 2001
CONTENTS
Editorial v - vi
MVA: a cuckoo in the vaccine nest?
Koert J. Stittelaar and Albert D.M.E. Osterhaus
LETTER TO THE EDITOR
Vaccines, CJD including variant CJD 3607
Subhash C. Arya
Development of Th1- mediated CD8+ effector T cells by vaccination with 3608-3614
epitope peptides encapsulated in pH-sensitive liposomes
Jin-Soo Chang, Myeong-Jun Choi, Hong-Seok Cheong and Kilhyoun Kim
Hepatitis A control in a refugee camp by active immunization 3615-3619
Bernard Kaic, Berislav Borcic, Mate Ljubicic, Inoslav Brkic and Ivanka
Mihaljevic
Construction of a live-attenuated bivalent vaccine virus against human 3620-3631
parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone
Tao Tao et al.
MMR and autism: further evidence against a causal association 3632-3635
C. Paddy Farrington, Elizabeth Miller and Brent Taylor
A quantitative assessment of the effectiveness of PRRSV vaccination in pigs 3636-3644
under experimental conditions
G. Nodelijk et al.
Impact of osmolality on burning sensations during and immediately after 3645-3651
intramuscular injection of 0.5 ml of vaccine suspensions in healthy adults
P. Nony et al.
Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 3652-3660
fusion protein vaccine, in homologous and heterologous prime-boost
regimens
S.H. van der Burg et al.
Inactivated recombinant plant virus protects dogs from a lethal challenge 3661-3670
with canine parvovirus
Jan P.M. Langeveld et al.
Anti-HBs after hepatitis B immunization with plasma-derived and 3671-3680
recombinant DNA-derived vaccines: binding to mutant HBsAg
R.A. Heijtink et al.
Protective immunity against influenza A virus induced by immunization 3681-3691
with DNA plasmid containing influenza M gene
Kenji Okuda et al.
Plasmid DNA-recombinant Opc protein complexes for nasal DNA 3692-3699
immunization
Alexis Musacchio et al.
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed 3700-3709
macaques
Koert J. Stittelaar et al.
Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, 3710-3719
progenipoietin-4, demonstrate potent immunological function
Glenn Y. Ishioka et al.
Cost of immunization with a locally produced, oral cholera vaccine in Viet 3720-3725
Nam
Abdollah B. Naficy et al.
A bacterially expressed peptide prevents experimental infection of primates 3726-3732
by the hepatitis E virus
Stanley W.K. Im et al.
Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees 3733-3743
immunized with human papillomavirus virus- like particles
Thomas J. Palker et al.
Granzyme B: a marker of risk for influenza in institutionalized older adults 3744-3751
Janet E. McElhaney et al.
Vaccination of pigs with a recombinant porcine adenovirus expressing the 3752-3758
gD gene from pseudorabies virus
Jef M. Hammond et al.
Mucosal immunization of mice using CpG DNA and/or mutants of the heat- 3759-3768
labile enterotoxin of Escherichia coli as adjuvants
Michael J. McCluskie, Risini D. Weeratna, John D. Clements and Heather
L. Davis
Contrasting Epstein- Barr virus-specific cytotoxic T cell responses to HLA 3769-3777
A2-restricted epitopes in humans and HLA transgenic mice: implications for
vaccine design
M. Bharadwaj, M. Sherritt, R. Khanna and D.J. Moss
Vaxfectin enhances antigen specific antibody titers and maintains Th1 type 3778-3786
immune responses to plasmid DNA immunization
Luane Reyes et al.
Intranasal immunogenicity of a cya crp-pabA mutant of Salmonella enterica 3787-3795
serotype Typhimurium for the horse
Abhineet S. Sheoran, John F. Timoney, Steven A. Tinge, Preeti Sundaram
and Roy Curtiss III
ERRATA
"Potential live vaccines for HIV" 3796
Mary Susan Burnett, Ning Wang, Matthias Hofmann and G. Barrie Kitto
"Mucosal immunization against hepatitis B virus by intranasal co- 3797
administration of recombinant hepatitis B surface antigen and recombinant
cholera toxin B subunit as an adjuvant"
Masanori Isaka et al.